The regulatory landscape for ANKTIVA saw critical developments regarding bladder cancer. ImmunityBio reported on January 20th that it held a Type B End-of-Phase meeting with the U.S. Food and Drug ...
With $202.3M in cash and an expanded $125M debt facility, ENGN is financially equipped to advance pivotal Cohort 1 and pursue ...
With 2026 set to be a banner year for M&A as buyers facing patent cliffs compete for a limited pool of late-stage assets [3], companies demonstrating disciplined pivotal execution and FDA alignment ...
The study highlights how color vision deficiency can delay bladder cancer diagnosis, increasing mortality risk and ...
Recognizing the sight of blood in urine, the most common first sign of bladder cancer, is often the impetus that leads people ...
Early detection and interception of pancreatic ductal adenocarcinoma (PDAC) remain the only realistic strategies to reduce ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results